The scientific community, and biopharma investors, respond on RFK Jr.

Taking stock of the drug industry, from the lab to the medicine chest

November 15, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Matt Rourke/AP STAT+ | Trump's pick of RFK Jr. at HHS: The scientific community, and biopharma investors, respond Leaders throughout the biopharma world and scientific community struggled to process news that President-elect Donald Trump had tapped RFK Jr. to lead HHS. By Jonathan Wosen, Adam Feuerstein, Allison DeAngelis, Matthew Herper, and Ed Silverman Opinion: Congress must act now to protect the future of diagnostic tests To protect patients and give test developers a clearer regulatory environment, Congress should pass the VALID Act. By Walter G. Johnson STAT+ | 'Worst imaginable' brain tumor yields, in some young people, to CAR-T therapy A CAR-T trial is one of several efforts that suggest there's hope of treating the "worst imaginable childhood brain tumor," known as DIPG.   By Jason Mast Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser